JP2010526814A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010526814A5 JP2010526814A5 JP2010507532A JP2010507532A JP2010526814A5 JP 2010526814 A5 JP2010526814 A5 JP 2010526814A5 JP 2010507532 A JP2010507532 A JP 2010507532A JP 2010507532 A JP2010507532 A JP 2010507532A JP 2010526814 A5 JP2010526814 A5 JP 2010526814A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound according
- halo
- trifluoromethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 239000003085 diluting agent Substances 0.000 claims 3
- 125000001475 halogen functional group Chemical group 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- -1 4-Fluoro-3-trifluoromethyl-phenyl Chemical group 0.000 claims 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- UEGFNRZYLNKXAD-UHFFFAOYSA-N 4-methylbenzenesulfonic acid;pyrimidine Chemical compound C1=CN=CN=C1.CC1=CC=C(S(O)(=O)=O)C=C1 UEGFNRZYLNKXAD-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000000112 colonic effect Effects 0.000 claims 1
- 210000004907 gland Anatomy 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91733107P | 2007-05-11 | 2007-05-11 | |
| US60/917,331 | 2007-05-11 | ||
| PCT/US2008/062143 WO2008140947A1 (en) | 2007-05-11 | 2008-05-01 | P70 s6 kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010526814A JP2010526814A (ja) | 2010-08-05 |
| JP2010526814A5 true JP2010526814A5 (OSRAM) | 2011-06-16 |
| JP5503532B2 JP5503532B2 (ja) | 2014-05-28 |
Family
ID=39765082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010507532A Expired - Fee Related JP5503532B2 (ja) | 2007-05-11 | 2008-05-01 | Ｐ７０ｓ６キナーゼ阻害剤 |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US8093383B2 (OSRAM) |
| EP (1) | EP2148880B1 (OSRAM) |
| JP (1) | JP5503532B2 (OSRAM) |
| KR (1) | KR101088219B1 (OSRAM) |
| CN (1) | CN101679439B (OSRAM) |
| AR (1) | AR066344A1 (OSRAM) |
| AU (1) | AU2008251692B2 (OSRAM) |
| BR (1) | BRPI0811212A2 (OSRAM) |
| CA (1) | CA2687265C (OSRAM) |
| CL (1) | CL2008001230A1 (OSRAM) |
| CO (1) | CO6241109A2 (OSRAM) |
| CR (1) | CR11106A (OSRAM) |
| DK (1) | DK2148880T3 (OSRAM) |
| DO (1) | DOP2009000257A (OSRAM) |
| EA (1) | EA016445B1 (OSRAM) |
| EC (1) | ECSP099721A (OSRAM) |
| ES (1) | ES2483726T3 (OSRAM) |
| GT (1) | GT200900292A (OSRAM) |
| HR (1) | HRP20140611T1 (OSRAM) |
| IL (1) | IL201564A (OSRAM) |
| MA (1) | MA31433B1 (OSRAM) |
| MX (1) | MX2009012075A (OSRAM) |
| MY (1) | MY154898A (OSRAM) |
| NZ (1) | NZ580423A (OSRAM) |
| PE (1) | PE20090887A1 (OSRAM) |
| PL (1) | PL2148880T3 (OSRAM) |
| PT (1) | PT2148880E (OSRAM) |
| RS (1) | RS53451B (OSRAM) |
| SI (1) | SI2148880T1 (OSRAM) |
| TN (1) | TN2009000446A1 (OSRAM) |
| TW (1) | TWI423805B (OSRAM) |
| UA (1) | UA99284C2 (OSRAM) |
| WO (1) | WO2008140947A1 (OSRAM) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA99284C2 (ru) * | 2007-05-11 | 2012-08-10 | Елі Ліллі Енд Компані | ИНГИБИТОРЫ р70 S6-КИНАЗЫ |
| WO2010019762A1 (en) * | 2008-08-13 | 2010-02-18 | Jenrin Discovery | Purine compounds as cannabinoid receptor blockers |
| EP2355820A1 (en) * | 2008-11-11 | 2011-08-17 | Eli Lilly and Company | P70 s6 kinase inhibitor and mtor inhibitor combination therapy |
| AR074072A1 (es) | 2008-11-11 | 2010-12-22 | Lilly Co Eli | Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme |
| AU2009314336B2 (en) * | 2008-11-11 | 2013-09-12 | Eli Lilly And Company | P70 S6 kinase inhibitor and EGFR inhibitor combination therapy |
| SI2396307T1 (sl) | 2009-02-11 | 2015-02-27 | Merck Patent Gmbh | Novi amino azaheterockliäśni karboksamidi |
| KR20120059525A (ko) | 2009-08-07 | 2012-06-08 | 메르크 파텐트 게엠베하 | 신규의 아자헤테로시클릭 화합물 |
| EP2491032B1 (en) | 2009-10-23 | 2014-04-16 | Eli Lilly and Company | Akt inhibitors |
| AR080643A1 (es) | 2010-02-03 | 2012-04-25 | Signal Pharm Llc | Identificacion de la mutacion de lkb1 como un biomarcador predictivo para la sensibilidad a inhibidores de la tor quinasa |
| UA110113C2 (xx) | 2010-07-29 | 2015-11-25 | Біциклічні азагетероциклічні карбоксаміди | |
| JP6014034B2 (ja) | 2010-07-29 | 2016-10-25 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 環式アミンアザヘテロ環式カルボキサミド |
| JP5897590B2 (ja) | 2010-11-24 | 2016-03-30 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | キナゾリンカルボキサミドアゼチジン |
| US9145392B2 (en) | 2011-09-12 | 2015-09-29 | Merck Patent Gmbh | Imidazole amines as modulators of kinase activity |
| BR112014005468A2 (pt) | 2011-09-12 | 2017-03-21 | Merck Patent Gmbh | derivados de aminopiridina para uso como moduladores de atividade quinase |
| ES2889757T3 (es) * | 2012-09-06 | 2022-01-13 | Plexxikon Inc | Compuestos y procedimientos para la modulación de quinasas e indicaciones para estos |
| AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
| ES2620119T3 (es) | 2012-11-16 | 2017-06-27 | Merck Patent Gmbh | Derivados heterocíclicos novedosos como moduladores de la actividad de quinasa |
| JP6280130B2 (ja) * | 2012-11-16 | 2018-02-14 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | キナーゼ活性のモジュレーターとしての新規イミダゾール−ピペリジニル誘導体 |
| BR112015011974A8 (pt) | 2012-11-29 | 2019-10-08 | Merck Patent Gmbh | derivados de azaquinazolina carboxamida, seus usos e processo para sua produção, medicamento e composição farmacêutica |
| MX370448B (es) * | 2013-03-11 | 2019-12-13 | Merck Patent Gmbh | Derivados de 6- [4- (1h-imidazol-2-il) piperidin-1-il] pirimidin-4-amina como moduladores de la actividad de cinasa. |
| CN105392499B (zh) | 2013-04-17 | 2018-07-24 | 西格诺药品有限公司 | 用于治疗癌症的包含tor激酶抑制剂和胞苷类似物的组合疗法 |
| WO2014172436A1 (en) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer |
| BR112015026021A2 (pt) | 2013-04-17 | 2017-07-25 | Signal Pharm Llc | terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer |
| BR112015026292B1 (pt) | 2013-04-17 | 2022-04-12 | Signal Pharmaceuticals, Llc | Uso de 1-etil-7-(2-metil-6-(1h-1,2,4-triazol-3-il)piridin-3-il)-3,4-dihidropirazino [2,3-b]pirazin-2(1h)- ona e métodos in vitro |
| US9937169B2 (en) | 2013-04-17 | 2018-04-10 | Signal Pharmaceuticals, Llc | Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy |
| EA030726B1 (ru) | 2013-04-17 | 2018-09-28 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | ФАРМАЦЕВТИЧЕСКИЕ СОСТАВЫ, СПОСОБЫ, ТВЕРДЫЕ ФОРМЫ И СПОСОБЫ ПРИМЕНЕНИЯ, ОТНОСЯЩИЕСЯ К 1-ЭТИЛ-7-(2-МЕТИЛ-6-(1H-1,2,4-ТРИАЗОЛ-3-ИЛ)ПИРИДИН-3-ИЛ)-3,4-ДИГИДРОПИРАЗИНО[2,3-b]ПИРАЗИН-2(1H)-ОНУ |
| CN113730412A (zh) | 2013-04-17 | 2021-12-03 | 西格诺药品有限公司 | 用二氢吡嗪并-吡嗪治疗癌症 |
| MX2015015880A (es) | 2013-05-29 | 2016-05-31 | Signal Pharm Llc | Composiciones farmaceuticas de 7-(6-(2-hidroxipropan-2-il)piridin- 3-il)-1-((trans)-4-metoxiciclohexil)-3,4-dihidropirazino[2,3-b]pi razin-2(1h)-ona, una forma solida del mismo y metodos de su uso. |
| US9771369B2 (en) | 2014-03-04 | 2017-09-26 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| KR102410696B1 (ko) | 2014-04-03 | 2022-06-17 | 메르크 파텐트 게엠베하 | 암 치료법의 조합 |
| NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
| WO2015160880A1 (en) | 2014-04-16 | 2015-10-22 | Signal Pharmaceuticals, Llc | SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF |
| WO2016040078A1 (en) * | 2014-09-10 | 2016-03-17 | Eli Lilly And Company | Substituted phenyl imidazolyl piperidyl compounds as p70s6k1 inhibitors |
| WO2016164641A1 (en) | 2015-04-08 | 2016-10-13 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| CN106187899B (zh) * | 2016-06-28 | 2019-07-16 | 绍兴文理学院 | 一种氟代氮杂芳烃的合成方法 |
| MY198676A (en) | 2017-06-22 | 2023-09-15 | Celgene Corp | Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection |
| JP2023551408A (ja) | 2020-11-16 | 2023-12-08 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | がん処置のためのキナーゼインヒビター組み合わせ |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL1004346C2 (nl) | 1996-10-23 | 1998-04-24 | Dsm Nv | Werkwijze voor het scheiden van een mengsel van enantiomeren in een geschikt oplosmiddel. |
| PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| EP1750727A2 (en) * | 2004-04-23 | 2007-02-14 | Exelixis, Inc. | Kinase modulators and methods of use |
| MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
| JP5274842B2 (ja) | 2004-12-28 | 2013-08-28 | エグゼリクシス， インコーポレイテッド | 免疫疾患、炎症疾患および増殖疾患の処置のためのセリン−スレオニンキナーゼモジュレーター（ｐ７０Ｓ６Ｋ、Ａｋｔ−１およびＡｋｔ−２）としての［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジンまたは［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジン化合物 |
| US20090325924A1 (en) | 2005-06-30 | 2009-12-31 | Stuart Edward | GPCR Agonists |
| JP5606734B2 (ja) | 2006-04-25 | 2014-10-15 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
| EP2037931A2 (en) | 2006-04-25 | 2009-03-25 | Astex Therapeutics Limited | Pharmaceutical combinations of pk inhibitors and other active agents |
| WO2008012635A2 (en) | 2006-07-26 | 2008-01-31 | Pfizer Products Inc. | Amine derivatives useful as anticancer agents |
| AR064416A1 (es) * | 2006-12-21 | 2009-04-01 | Cancer Rec Tech Ltd | Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas. |
| UA99284C2 (ru) * | 2007-05-11 | 2012-08-10 | Елі Ліллі Енд Компані | ИНГИБИТОРЫ р70 S6-КИНАЗЫ |
-
2008
- 2008-01-05 UA UAA200911422A patent/UA99284C2/ru unknown
- 2008-04-23 TW TW097114908A patent/TWI423805B/zh not_active IP Right Cessation
- 2008-04-29 AR ARP080101808A patent/AR066344A1/es unknown
- 2008-04-29 CL CL2008001230A patent/CL2008001230A1/es unknown
- 2008-04-29 PE PE2008000756A patent/PE20090887A1/es not_active Application Discontinuation
- 2008-05-01 JP JP2010507532A patent/JP5503532B2/ja not_active Expired - Fee Related
- 2008-05-01 HR HRP20140611AT patent/HRP20140611T1/hr unknown
- 2008-05-01 CA CA2687265A patent/CA2687265C/en not_active Expired - Fee Related
- 2008-05-01 MX MX2009012075A patent/MX2009012075A/es active IP Right Grant
- 2008-05-01 CN CN2008800156864A patent/CN101679439B/zh not_active Expired - Fee Related
- 2008-05-01 KR KR1020097023455A patent/KR101088219B1/ko not_active Expired - Fee Related
- 2008-05-01 ES ES08747285.8T patent/ES2483726T3/es active Active
- 2008-05-01 SI SI200831223T patent/SI2148880T1/sl unknown
- 2008-05-01 PT PT87472858T patent/PT2148880E/pt unknown
- 2008-05-01 DK DK08747285.8T patent/DK2148880T3/da active
- 2008-05-01 BR BRPI0811212-6A2A patent/BRPI0811212A2/pt not_active IP Right Cessation
- 2008-05-01 PL PL08747285T patent/PL2148880T3/pl unknown
- 2008-05-01 EP EP08747285.8A patent/EP2148880B1/en active Active
- 2008-05-01 RS RS20140385A patent/RS53451B/sr unknown
- 2008-05-01 EA EA200971051A patent/EA016445B1/ru not_active IP Right Cessation
- 2008-05-01 WO PCT/US2008/062143 patent/WO2008140947A1/en not_active Ceased
- 2008-05-01 AU AU2008251692A patent/AU2008251692B2/en not_active Ceased
- 2008-05-01 NZ NZ580423A patent/NZ580423A/en not_active IP Right Cessation
- 2008-05-01 MY MYPI20094763A patent/MY154898A/en unknown
-
2009
- 2009-03-02 US US12/396,103 patent/US8093383B2/en not_active Expired - Fee Related
- 2009-10-15 IL IL201564A patent/IL201564A/en not_active IP Right Cessation
- 2009-10-28 TN TNP2009000446A patent/TN2009000446A1/fr unknown
- 2009-11-09 EC EC2009009721A patent/ECSP099721A/es unknown
- 2009-11-10 DO DO2009000257A patent/DOP2009000257A/es unknown
- 2009-11-10 CO CO09127778A patent/CO6241109A2/es active IP Right Grant
- 2009-11-10 CR CR11106A patent/CR11106A/es unknown
- 2009-11-10 GT GT200900292A patent/GT200900292A/es unknown
- 2009-12-07 MA MA32404A patent/MA31433B1/fr unknown
-
2011
- 2011-11-30 US US13/307,560 patent/US20120071490A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010526814A5 (OSRAM) | ||
| JP2013537203A5 (OSRAM) | ||
| JP2011519854A5 (OSRAM) | ||
| JP2010504343A5 (OSRAM) | ||
| JP2011513305A5 (OSRAM) | ||
| JP2006514012A5 (OSRAM) | ||
| JP2010501478A5 (OSRAM) | ||
| JP2013513613A5 (OSRAM) | ||
| JP2014503574A5 (OSRAM) | ||
| JP2008510828A5 (OSRAM) | ||
| JP2019522055A5 (OSRAM) | ||
| CA2687265A1 (en) | P70 s6 kinase inhibitors | |
| WO2009010416A3 (en) | Inhibitors of 11b-hydroxysteroid dehydrogenase | |
| JP2013544860A5 (OSRAM) | ||
| JP2012508274A5 (OSRAM) | ||
| JP2011527666A5 (OSRAM) | ||
| JP2010502767A5 (OSRAM) | ||
| JP2011505347A5 (OSRAM) | ||
| JP2015522650A5 (OSRAM) | ||
| JP2014528403A5 (OSRAM) | ||
| CN113784963A (zh) | 用作ret激酶抑制剂的化合物及其应用 | |
| JP2012507535A5 (OSRAM) | ||
| JP2009516697A5 (OSRAM) | ||
| JP2013502441A5 (OSRAM) | ||
| TW200643013A (en) | Pyrazoles |